
|Videos|October 11, 2016
Promising Alzheimer Antibody-Based Immunotherapy
Author(s)Bobby Lazzara, MD
Dr. Bobby Lazzara reports on a clinical trial of aducanumab, a human monoclonal antibody, in patients with prodromal or mild Alzheimer disease.
Advertisement
Aducanumab, a human monoclonal antibody, selectively targets aggregated amyloid-β. In this Medical News Minute, developed exclusively for Neurology Times, Dr. Bobby Lazzara discusses a
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Women Physicians Day 2026: Supporting Women With MS Through Reproductive and Life Stage Transitions
2
National Women Physicians Day: Strengthening the Pathway for Women Physicians in Neuroscience
3
Women Physicians Day 2026: Sex-Specific Clinical Considerations in Women With Epilepsy
4
National Women Physicians Day: Perspectives From Riley Bove, MD
5











